Prestige Consumer Healthcare Inc. Completes Major Acquisition of Breathe Right® Brand
Key Highlights of the Transaction
- Acquisition Closed: Prestige Consumer Healthcare Inc. (NYSE: PBH) has finalized the acquisition of the Breathe Right® brand and several other brands from Foundation Consumer Healthcare.
- Purchase Price: The total acquisition price is \$1.045 billion, with anticipated tax benefits valued at \$150 million. This brings the net cost to approximately \$900 million.
- Strategic Expansion: Breathe Right®, an iconic and market-leading brand in the nasal strip category, will now become Prestige’s largest brand. This acquisition marks a significant expansion into a new product category for Prestige.
- Financing Structure: Prestige financed the transaction using a mix of available cash and proceeds from a newly completed Term Loan B.
- Transaction Details: The transaction was finalized according to the asset purchase agreement announced on March 20, 2026. Further details, including strategic benefits, are available in a company presentation dated March 20, 2026.
Implications for Shareholders & Potential Price Sensitivity
- Brand Portfolio Enhancement: The addition of Breathe Right® not only strengthens Prestige’s portfolio but also represents a substantial entry into the nasal strip category, potentially driving future revenue growth and margin expansion.
- Largest Brand Status: Breathe Right® is set to become Prestige’s largest brand, which may materially impact the company’s market positioning and competitive advantage.
- Financial Leverage: The use of a new Term Loan B to finance the deal may affect Prestige’s capital structure and leverage ratios. Investors should monitor future updates regarding debt repayment and integration progress.
- Tax Benefits: The anticipated \$150 million in tax benefits will reduce the effective purchase price, improving financial efficiency.
- Expansion into New Category: The acquisition broadens Prestige’s reach in consumer healthcare, potentially opening up cross-marketing and distribution synergies across its existing brands.
- Investor Communications: Investors can find further details and presentations about the transaction on the company’s investor relations website, which may offer additional insight into forecasted financial impacts and strategic rationale.
Company Overview
Prestige Consumer Healthcare markets, sells, manufactures, and distributes a diverse portfolio of consumer healthcare products across the U.S., Canada, Australia, and select international markets. Its brands include Monistat®, Summer’s Eve®, BC®, Clear Eyes®, TheraTears®, DenTek®, Dramamine®, Fleet®, Chloraseptic®, Luden’s®, Compound W®, Little Remedies®, Boudreaux’s Butt Paste®, Nix®, Debrox®, Gaviscon®, Hydralyte®, and Fess®.
The addition of Breathe Right® further diversifies Prestige’s product offerings and strengthens its presence in the consumer healthcare space.
Investor Relations Contact
For further inquiries, shareholders and analysts are encouraged to contact Phil Terpolilli, CFA, at 914-524-6819 or via email at [email protected].
Conclusion
This acquisition represents a transformative step for Prestige Consumer Healthcare, positioning the company for enhanced growth and market leadership. The strategic and financial implications of the deal are likely to be significant, with potential to influence share value in the near term.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors are urged to review official company filings and consult with their financial advisors before making investment decisions. The author does not assume responsibility for any investment actions taken based on this article.
